David K. Lee, head of Shire’s Global Genetic Diseases and Oncology franchises, will run the US subsidiary, which was Shire’s oncology business.

Servier has selected the head of its new U.S. subsidiary. Servier Pharmaceuticals U.S. was formed after Servier acquired Shire’s oncology business in April 2018 for $2.4 billion.

Its new leader will be David K. Lee, who currently is the head of Shire’s Global Genetic Diseases and Oncology franchises and previously ran Baxalta’s oncology business before Shire purchased. In addition to building out Servier’s new U.S. activities, Lee will be responsible for running the Boston-based business that manages the one marketed product (Oncaspar) Servier obtained as part of the Shire acquisition.

Lee will begin his new job once the deal has closed, which is expected to take place in the third quarter of 2018. He will report to Servier group president Olivier Laureau. Lee is charged with establishing “an immediate and direct commercial presence in the U.S.”